He hasn't executed on the MDA with AmeriMark and MediCann EU relative to wholesale of CelebC*. That was potentially about $4 mil left on the table that would have been recorded this past FY.
Now expected revenue is between ~$2.8-$4.6 mil?
They've paid insiders $1 mil in first two quarters of this past FY, and there is literally no update on the alleged "fast track" of an alleged alternative prescription drug to opioid prescription meds.
And, really, OMHE communications with public/shareholders has been pretty bad for the past 1.5 years.
From the last official PR on 5/21/18, they recycled the NASDAQ uplist gimmick that they already used last year. There was relatively little new "news"; other than the OMHE jumping on the "blockchain" train. More likely than not, that's a failure out of the gate; since OMHE isn't a technology company.
He doesn't reply to emails or telephone calls.
Altho, FB and twitter might help. But those tools just came on board in the past 2-3 weeks.